General
Preferred name
ALCLOFENAC
Synonyms
W 7320 ()
MY 101 ()
BRN 2116510 ()
W-7320 ()
W7320 ()
Allopydin ()
MY-101 ()
Medifenac ()
Neosten ()
Epinal ()
Alclofenaco ()
Reufenac ()
Neoston ()
Mervan ()
Zumaril ()
Prinalgin ()
P&D ID
PD013495
CAS
22131-79-9
Tags
available
drug
First approval
1969
Drug Status
approved
withdrawn
Max Phase
4.0
Drug indication
rheumatic disease
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY The lethal dose ; orally: 1100 (mice), 1050 (rats) mg / kg ; ; under the skin: 600 (mice), 630 (rats) mg / kg; intraperitoneally: 550 (mice), 530 (rats) mg / kg
PRICE 74
DESCRIPTION Alclofenac (W-7320) has a significant effect on the acute phase protein response and the degree of L-tryptophan binding to plasma protein and can be used in the treatment of patients with chronic rheumatism. (TargetMol Bioactive Compound Library)
Compound Sets
14
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
Withdrawn 2.0
External IDs
28
Properties
(calculated by RDKit )
Molecular Weight
226.04
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
2.53
TPSA
46.53
Fraction CSP3
0.18
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Indication
rheumatoid arthritis
Target
PTGS1
Prostaglandin Receptor
MOA
cyclooxygenase inhibitor
ATC
M01AB06
Toxicity type
dermatological
Pathway
GPCR/G protein
Source data